Lindsay Androski is President and Chief Executive Officer of Arbutus Biopharma Corp (ABUS). The company reported total compensation of $1,369,013 for fiscal year 2025.
| Salary | $437,750 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $714,751 |
| Non-equity incentive plan | $216,512 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $1,369,013 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Arbutus Biopharma Corp filed April 14, 2026, accession 0001140361-26-014623.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Michael McElhaugh | Former Interim President and Chief Executive Officer | $3,578,150 |
| Tuan Nguyen | Chief Financial Officer | $2,416,995 |
| David Hastings | Former Chief Financial Officer | $2,218,362 |
| Lindsay Androski this page | President and Chief Executive Officer | $1,369,013 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Arbutus Biopharma Corp compensation brief.
Lindsay Androski's compensation sits inside Arbutus Biopharma Corp's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.